Video

Dr. Olin on FLT3 Inhibitor Research in AML

Author(s):

Rebecca L. Olin, MD, MSCE

In Partnership With:

Rebecca L. Olin, MD, MSCE, discusses research surrounding FLT3 inhibitors as a treatment for patients with acute myeloid leukemia.

Rebecca L. Olin, MD, MSCE, associate professor, Department of Medicine (Hematology/Oncology), Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses research surrounding FLT3 inhibitors as a treatment for patients with acute myeloid leukemia.

Midostaurin (Rydapt) in combination with 7+3 has become the standard of care in patients with FLT3-positive disease at diagnosis due to the overall survival benefit that was seen in the RATIFY trial, explains Olin. Gilteritinib (Xospata) is a different type of FLT3 inhibitor, which was looked at in the relapsed/refractory setting and compared with standard chemotherapy. Results showed that when gilteritinib is given as monotherapy, it leads to a significant improvement in response rate and survival, thereby making it a reasonable standard of care in the second-line setting, says Olin.

These agents will be examined in the maintenance setting, as well. There are already some data on sorafenib (Nexavar) and midostaurin in the maintenance setting, and an ongoing trial is also examining gilteritinib as a maintenance option, according to Olin.

Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Related Content
Jorge E. Cortes, MD, of Georgia Cancer Center
November 21st 2024

An Era of Firsts in CML: Asciminib Challenges SOC TKIs

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

Acute Myeloid Leukemia
November 15th 2024

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Alex F. Herrera, MD
November 14th 2024

Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL